Acute Liver Failure in the United States

 

 Buy Article Permissions and Reprints

ABSTRACT

In the last 5 years the use of a multicenter approach has helped to define acute liver failure (ALF) in the United States. Drug-related hepatotoxicity comprises more than 50% of cases of ALF, including acetaminophen toxicity (40%) and idiosyncratic drugs (approximately 12%). Nearly 20% of cases remain of unknown etiology. Outcome of ALF is determined by etiology; by the degree of hepatic encephalopathy present on admission; and by complications, principally infection. More than 43% survive without a transplant, 28% die, and 29% undergo liver transplantation. Liver support machines have had no impact on this condition to date. A trial of N-acetylcysteine for the treatment of ALF not related to acetaminophen toxicity is underway. Future research in ALF in the United States should focus on limiting the number of cases related to drugs, searching for causes of the indeterminate cases, and developing more effective temporary liver support.

REFERENCES

• 1 Trey C, Davidson C S. The management of fulminant hepatic failure. In: Popper H, Schaffner F, eds. Progress in Liver Diseases New York: Grune & Stratton 1970: 282-298
  Google Scholar
• 2 Ritt D J, Whelan G, Werner D J. et al . Acute hepatic necrosis with stupor or coma. An analysis of thirty-one patients.  Medicine . 1969;  48 151-72
  PubMedGoogle Scholar
• 3 Lee W M, Schiødt F V. Fulminant hepatic failure. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff's Diseases of the Liver, 8th ed Philadelphia: Lippincott-Raven 1999: 879-895
  Google Scholar
• 4 Benhamou J-P. Fulminant and subfulminant liver failure: definition and causes. In: Williams R, Hughes RD, eds. Acute Liver Failure. Improved Understanding and Better Therapy London: SmithKline Beecham Pharmaceuticals 1991: 6-10
  Google Scholar
• 5 Hoofnagle J H, Carithers R L, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop.  Hepatology . 1995;  21 240-252
  CrossrefPubMedGoogle Scholar
• 6 Rakela J, Mosley J W, Edwards V M, and the Acute Hepatic Failure Study Group. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure.  Dig Dis Sci . 1991;  36 1223-1228
  CrossrefPubMedGoogle Scholar
• 7 Schiødt F V, Atillasoy E, Shakil A O. et al . Etiology and outcome for 295 patients with acute liver failure in the United States.  Liver Transpl Surg . 1999;  5 29-34
  CrossrefPubMedGoogle Scholar
• 8 Shakil A O, Kramer D, Mazariegos G V. et al . Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria.  Liver Transpl . 2000;  6 163-169
  PubMedGoogle Scholar
• 9 Ostapowicz G A, Fontana R J, Schiødt F V, et al., Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med .  2002;  137 947-954
  CrossrefPubMedGoogle Scholar
• 10 Bernal W. Changing patterns of causation and the use of transplantation in the United Kingdom.  Semin Liver Dis . 2003;  23 227-238
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 Makin A J, Wendon J, Williams R. A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993).  Gastroenterology . 1995;  109 1907-1916
  CrossrefPubMedGoogle Scholar
• 12 Trigo P L, Lendoire J C, Braslavsky G A. et al . Etiology and outcome of 83 patients with fulminant hepatic failure in adults. Experience of an Argentinian liver transplant unit.  Hepatology . 2001;  34 657A
  PubMedGoogle Scholar
• 13 Acharya S K, Dasarathy S, Kumer T L. et al . Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome.  Hepatology . 1996;  23 1448-1455
  CrossrefPubMedGoogle Scholar
• 14 Uemoto S, Inomata Y, Sakurai T. et al . Living donor liver transplantation for fulminant hepatic failure.  Transplantation . 2000;  70 152-157
  PubMedGoogle Scholar
• 15 Teo E K, Ostapowicz G A, Hussain M, and US ALF Study Group. Hepatitis B infection in patients with acute liver failure in the United States.  Hepatology . 2001;  33 972-976
  CrossrefPubMedGoogle Scholar
• 16 Sato S, Suzuki K, Akahane Y. et al . Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis.  Ann Intern Med . 1995;  122 241-248
  PubMedGoogle Scholar
• 17 Chan H LY, Hussain M, Lok A SF. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion.  Hepatology . 1999;  29 976-984
  CrossrefPubMedGoogle Scholar
• 18 Umemura T, Tanaka E, Lee W M. et al . The role of SEN virus infection in various liver diseases from different geographical regions.  Hepatology . 2002;  36 646A
  PubMedGoogle Scholar
• 19 Larson A M, Ostapowicz G, Fontana R J, et al., Outcome of acetaminophen-induced acute liver failure in the USA in suicidal versus accidental overdose: preliminary results of a prospective multi-center trial. Hepatology .  2000;  32 A396
  PubMedGoogle Scholar
• 20 Shayiq R M, Roberts D W, Rothstein K. et al . Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: an explanation for high acetaminophen dosage in humans without hepatic injury.  Hepatology . 1999;  29 451-463
  CrossrefPubMedGoogle Scholar
• 21 Schiødt F V, Rochling F J, Casey D L, Lee W M. Acetaminophen toxicity in an urban county hospital.  N Engl J Med . 1997;  337 1112-1117
  CrossrefPubMedGoogle Scholar
• 22 Schiødt F V, Lee W M, Bondesen S, Ott P, Christensen E. Influence of acute and chronic alcohol intake on the clinical course and outcome in acetaminophen overdose.  Aliment Pharmacol Ther . 2002;  16 707-715
  CrossrefPubMedGoogle Scholar
• 23 Prescott L F. Paracetamol, alcohol and the liver.  Br J Clin Pharmacol . 2000;  49 291-301
  CrossrefPubMedGoogle Scholar
• 24 US Food and Drug Administration. www.fda.gov/cder/ livertox/default.htm
• 25 Moynihan R. FDA fails to reduce accessibility of paracetamol despite 450 deaths a year.  BMJ . 2002;  325 678
  CrossrefPubMedGoogle Scholar
• 26 Fontana R J, McCashland T M, Benner K G. et al . Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group.  Liver Transpl Surg . 1999;  5 480-484
  CrossrefPubMedGoogle Scholar
• 27 Murphy E J, Davern T J, Shakil A O. et al . Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group.  Dig Dis Sci . 2000;  45 549-553
  CrossrefPubMedGoogle Scholar
• 28 Schiødt F V, Davern T A, Shakil O, and the Acute Liver Failure Study Group. Viral hepatitis-associated acute liver failure.  Am J Gastroenterol . 2003;  98 448-453
  PubMedGoogle Scholar
• 29 Villamil F G, Hu K Q, Yu C H. et al . Detection of hepatitis C virus with RNA polymerase chain reaction in fulminant hepatic failure.  Hepatology . 1995;  22 1379-1386
  CrossrefPubMedGoogle Scholar
• 30 O'Grady J G, Alexander G J, Hayllar K M, Williams R. Early indicators of prognosis in fulminant hepatic failure.  Gastroenterology . 1989;  97 439-445
  PubMedGoogle Scholar
• 31 Williams R. Classification, etiology, and considerations of outcome in acute liver failure.  Semin Liver Dis . 1996;  16 343-348
  Article in Thieme ConnectPubMedGoogle Scholar
• 32 Mitchell I, Bihari D, Chang R, Wendon J, Williams R. Earlier identification of patients at risk from acetaminophen-induced acute liver failure.  Crit Care Med . 1998;  26 279-284
  PubMedGoogle Scholar
• 33 Lee W M, Galbraith R M, Watt G H. et al . Predicting survival in fulminant hepatic failure using serum Gc protein concentrations.  Hepatology . 1995;  21 101-105
  CrossrefPubMedGoogle Scholar
• 34 Schiødt F V, Ott P, Tygstrup N, Dahl B, Bondesen S. Temporal profile of total, bound and free Gc globulin after acetaminophen overdose.  Liver Transplantation . 2001;  7 732-738
  CrossrefPubMedGoogle Scholar
• 35 Lee W M, Galbraith R M. The extracellular actin-scavenger system and actin toxicity.  N Engl J Med . 1992;  326 1335-1341
  PubMedGoogle Scholar
• 36 Dahl B, Schiødt F V, Ott P. et al . Plasma gelsolin is reduced in trauma patients.  Shock . 1999;  12 102-104
  PubMedGoogle Scholar
• 37 Schiødt F V, Balko J, Gammage S J, and the ALF Study Group. Gc-globulin and prognosis in acute liver failure.  Hepatology . 2002;  32 291A
  PubMedGoogle Scholar
• 38 Bloomer J R, Waldmann T A, McIntire K R, Klatskin G. Serum alpha-fetoprotein in patients with severe hepatic necrosis.  Gastroenterology . 1977;  72 479-482
  PubMedGoogle Scholar
• 39 Ostapowicz G, McCashland T M, Shakil O, and the ALF Study Group. An increase in alpha-fetoprotein predicts survival in acute liver failure.  Hepatology . 1999;  30 165A
  PubMedGoogle Scholar
• 40 Squires R H, Sokol R J, Shneider B I. et al . Encephalopathy (EN) at presentation predicts outcome for children with acute liver failure (ALF).  Hepatology . 2002;  36 167A
  PubMedGoogle Scholar
• 41 Hay J E, McGuire B, Ostapowicz G, Lee W M. Management of fulminant hepatic failure in the USA: results from a survey of 14 liver transplant programs.  Gastroenterology . 2001;  120(Suppl 1) 542A
  PubMedGoogle Scholar
• 42 Vaquero J, Schiodt F V, Chung C. et al . Predictors of progression to deep hepatic encephalopathy in acute liver failure.  Hepatology . 2002;  32 221A
  PubMedGoogle Scholar
• 43 Ostapowicz G, Lee H. Acute liver failure: the Western experience.  J Gastroenterol Hepatol . 2000;  15 480-488<
  CrossrefPubMedGoogle Scholar